Robert Driscoll
Stock Analyst at Wedbush
(1.25)
# 3,373
Out of 4,829 analysts
159
Total ratings
28.57%
Success rate
-11.57%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Robert Driscoll
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| HOWL Werewolf Therapeutics | Maintains: Outperform | $8 → $6 | $0.80 | +650.19% | 3 | May 9, 2025 | |
| RVMD Revolution Medicines | Reiterates: Outperform | $67 | $40.42 | +65.76% | 5 | Apr 28, 2025 | |
| ZNTL Zentalis Pharmaceuticals | Reiterates: Neutral | $4 | $1.23 | +225.20% | 10 | Mar 28, 2025 | |
| GLUE Monte Rosa Therapeutics | Maintains: Outperform | $15 → $17 | $4.09 | +315.65% | 4 | Mar 21, 2025 | |
| ARVN Arvinas | Downgrades: Neutral | $57 → $12 | $6.61 | +81.54% | 9 | Mar 12, 2025 | |
| DAWN Day One Biopharmaceuticals | Reiterates: Outperform | $32 | $6.45 | +396.12% | 6 | Feb 26, 2025 | |
| KURA Kura Oncology | Maintains: Outperform | $34 → $36 | $5.76 | +525.00% | 8 | Feb 6, 2025 | |
| IDYA IDEAYA Biosciences | Reiterates: Outperform | $52 | $17.42 | +198.51% | 9 | Dec 17, 2024 | |
| TYRA Tyra Biosciences | Reiterates: Outperform | $28 | $10.10 | +177.23% | 8 | Oct 25, 2024 | |
| BDTX Black Diamond Therapeutics | Reiterates: Outperform | $16 | $1.64 | +875.61% | 10 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $30 | $8.28 | +262.32% | 7 | Oct 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $25 → $22 | $1.13 | +1,846.90% | 10 | Oct 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $85 → $51 | $6.45 | +690.70% | 1 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $5 | $0.61 | +719.81% | 8 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $36 | $7.54 | +377.45% | 4 | Sep 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $11 | $1.60 | +587.50% | 3 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $13 | $4.20 | +209.52% | 7 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11 → $13 | $1.14 | +1,040.35% | 4 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $74 | $25.56 | +189.51% | 7 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $8 | $1.82 | +339.56% | 3 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $7 | $1.18 | +493.22% | 8 | Jun 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $3 → $8 | $0.93 | +761.70% | 9 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $8 | $0.34 | +2,232.36% | 7 | May 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $52 | $7.71 | +574.45% | 5 | Nov 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $2 → $4 | $3.23 | +23.84% | 4 | May 19, 2020 |
Werewolf Therapeutics
May 9, 2025
Maintains: Outperform
Price Target: $8 → $6
Current: $0.80
Upside: +650.19%
Revolution Medicines
Apr 28, 2025
Reiterates: Outperform
Price Target: $67
Current: $40.42
Upside: +65.76%
Zentalis Pharmaceuticals
Mar 28, 2025
Reiterates: Neutral
Price Target: $4
Current: $1.23
Upside: +225.20%
Monte Rosa Therapeutics
Mar 21, 2025
Maintains: Outperform
Price Target: $15 → $17
Current: $4.09
Upside: +315.65%
Arvinas
Mar 12, 2025
Downgrades: Neutral
Price Target: $57 → $12
Current: $6.61
Upside: +81.54%
Day One Biopharmaceuticals
Feb 26, 2025
Reiterates: Outperform
Price Target: $32
Current: $6.45
Upside: +396.12%
Kura Oncology
Feb 6, 2025
Maintains: Outperform
Price Target: $34 → $36
Current: $5.76
Upside: +525.00%
IDEAYA Biosciences
Dec 17, 2024
Reiterates: Outperform
Price Target: $52
Current: $17.42
Upside: +198.51%
Tyra Biosciences
Oct 25, 2024
Reiterates: Outperform
Price Target: $28
Current: $10.10
Upside: +177.23%
Black Diamond Therapeutics
Oct 8, 2024
Reiterates: Outperform
Price Target: $16
Current: $1.64
Upside: +875.61%
Oct 3, 2024
Reiterates: Outperform
Price Target: $30
Current: $8.28
Upside: +262.32%
Oct 1, 2024
Maintains: Outperform
Price Target: $25 → $22
Current: $1.13
Upside: +1,846.90%
Sep 20, 2024
Maintains: Outperform
Price Target: $85 → $51
Current: $6.45
Upside: +690.70%
Sep 20, 2024
Reiterates: Outperform
Price Target: $5
Current: $0.61
Upside: +719.81%
Sep 18, 2024
Reiterates: Outperform
Price Target: $36
Current: $7.54
Upside: +377.45%
Aug 13, 2024
Reiterates: Outperform
Price Target: $11
Current: $1.60
Upside: +587.50%
Aug 9, 2024
Reiterates: Outperform
Price Target: $13
Current: $4.20
Upside: +209.52%
Aug 8, 2024
Maintains: Outperform
Price Target: $11 → $13
Current: $1.14
Upside: +1,040.35%
Aug 8, 2024
Reiterates: Outperform
Price Target: $74
Current: $25.56
Upside: +189.51%
Aug 7, 2024
Reiterates: Outperform
Price Target: $8
Current: $1.82
Upside: +339.56%
Jun 7, 2024
Reiterates: Outperform
Price Target: $7
Current: $1.18
Upside: +493.22%
May 9, 2024
Upgrades: Outperform
Price Target: $3 → $8
Current: $0.93
Upside: +761.70%
May 3, 2024
Reiterates: Outperform
Price Target: $8
Current: $0.34
Upside: +2,232.36%
Nov 8, 2023
Reiterates: Outperform
Price Target: $52
Current: $7.71
Upside: +574.45%
May 19, 2020
Upgrades: Outperform
Price Target: $2 → $4
Current: $3.23
Upside: +23.84%